MXC MGC Pharmaceuticals Ltd

TIDMMXC

MGC Pharmaceuticals Limited

12 February 2021

 
 12 February   MGC Pharma Investor Presentation Today - Friday 12th 
     2021                          February 2021 
  ASX Code: 
     MXC 
  LSE Code: 
     MXC 
 

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, 'MGC Pharma' or 'the Company'), the first and currently only medicinal cannabis company to be listed on the LSE, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments and Vox Markets.

Roby Zomer, CEO and Managing Director, and Brett Mitchell, Executive Chairman, will be presenting and answering questions from attendees.

MGC Pharma is a European based and dual listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines.

The webinar will take place at 10am GMT (9pm Sydney) today, Friday 12th February 2021. Please register your interest at https://voxmarkets.brand.live/c/vox-markets-and-turner-pope-webinar-friday-february-12th .

--Ends--

For further information please contact:

 
 UK PR Tavistock - Tavistock          MGC Pharmaceuticals Ltd 
  Charlies Vivian +44 20 7920 3150     Roby Zomer 
  Charles.Vivian@tavistock.co.uk       CEO & Managing Director 
                                       +61 8 6382 3390 
  PR/IR Advisors - Media & Capital     info@mgcpharma.com.au 
  Partners 
  Rod Hinchcliffe (IR) +61 412 277     Corporate Broker - Turner Pope 
  377                                  Investments 
  Rod.Hinchcliffe@mcpartners.com.au    Andy Thacker 
                                       Andy.Thacker@TurnerPope.com 
                                       Zoe Alexander 
                                       +44 203 657 0050 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. The most advanced of these is ArtemiC(TM) , which recently successfully completed Phase II trials as a potential aid to the recovery of moderate COVID-19 patients.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels :

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAQLLBFFLLXBBX

(END) Dow Jones Newswires

February 12, 2021 02:00 ET (07:00 GMT)

Grafico Azioni MGC Pharmaceuticals (ASX:MXC)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni MGC Pharmaceuticals (ASX:MXC)
Storico
Da Apr 2023 a Apr 2024